Sulfasalazine-induced drug rash with eosinophilia and systemic symptoms syndrome in a seronegative spondyloarthritis patient: A Case report (Record no. 15863)

MARC details
000 -LEADER
fixed length control field a
003 - CONTROL NUMBER IDENTIFIER
control field OSt
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20211231113227.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 211231b xxu||||| |||| 00| 0 eng d
040 ## - CATALOGING SOURCE
Original cataloging agency AIKTC-KRRC
Transcribing agency AIKTC-KRRC
100 ## - MAIN ENTRY--PERSONAL NAME
9 (RLIN) 15282
Author Sah, Naresh
245 ## - TITLE STATEMENT
Title Sulfasalazine-induced drug rash with eosinophilia and systemic symptoms syndrome in a seronegative spondyloarthritis patient: A Case report
250 ## - EDITION STATEMENT
Volume, Issue number Vol.53(5), Sep-Oct
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Place of publication, distribution, etc. Mumbai
Name of publisher, distributor, etc. Wolter Kluwer
Year 2021
300 ## - PHYSICAL DESCRIPTION
Pagination 391-393p.
520 ## - SUMMARY, ETC.
Summary, etc. The objectives were to evaluate drug rash with eosinophilia and systemic symptoms syndrome due<br/>to sulfasalazine and to carry out the pharmacoeconomic assessment associated with this adverse<br/>drug reaction (ADR). A 37‑year woman was presented with rashes, fever, cough, and dyspnea.<br/>In the past 3 months, she was on sulfasalazine for inflammatory polyarthritis and seronegative<br/>spondyloarthritis. The diagnosis was based on raised eosinophils count, breathing difficulty, and<br/>typical pattern of rashes. Significant improvement was seen after discontinuation of sulfasalazine<br/>and with the initiation of parenteral corticosteroids. The casualty of this ADR was “probable” based on<br/>RegiSCAR, WHO, and Naranjo casualty assessment scales. Preventability, severity was assessed<br/>and total cost for management of the ADR was found to be ` 12,126. Thus, ADRs not only adds to<br/>patient sufferings but also increase the economic burden. Health‑care providers need to be made<br/>aware of potentially fatal ADRs associated with sulfa drugs and should be keen to report such ADRs<br/>to drug safety authorities.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
9 (RLIN) 4774
Topical term or geographic name entry element PHARMACOLOGY
700 ## - ADDED ENTRY--PERSONAL NAME
9 (RLIN) 15283
Co-Author Ramaiah, Balakeshwa
773 0# - HOST ITEM ENTRY
International Standard Serial Number 0253-7613
Title Indian Journal of Pharmacology
Place, publisher, and date of publication Andheri - Mumbai Wolters Kluwer India Private Limited
856 ## - ELECTRONIC LOCATION AND ACCESS
URL https://www.ijp-online.com/temp/IndianJPharmacol535391-2153833_055858.pdf
Link text Click here
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme Dewey Decimal Classification
Koha item type Articles Abstract Database
Holdings
Withdrawn status Lost status Source of classification or shelving scheme Damaged status Not for loan Home library Current library Shelving location Date acquired Total Checkouts Barcode Date last seen Price effective from Koha item type
    Dewey Decimal Classification     School of Pharmacy School of Pharmacy Archieval Section 31/12/2021   2021-2022680 31/12/2021 31/12/2021 Articles Abstract Database
Unique Visitors hit counter Total Page Views free counter
Implemented and Maintained by AIKTC-KRRC (Central Library).
For any Suggestions/Query Contact to library or Email: librarian@aiktc.ac.in | Ph:+91 22 27481247
Website/OPAC best viewed in Mozilla Browser in 1366X768 Resolution.